Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

Journal article

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group None., (2024), Kidney Int, 105, S117 - S314

EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE FROM JAPAN: EXPLORATORY ANALYSES FROM EMPA-KIDNEY

Journal article

HERRINGTON W., (2024), Clinical and Experimental Nephrology

[2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes].

Journal article

Marx N. et al, (2024), G Ital Cardiol (Rome), 25, e1 - e103

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

Journal article

EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 39 - 50

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

Journal article

EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Journal article

RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Journal article

Mayne K. et al, (2023), Journal of the American Society of Nephrology

SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA

Journal article

Mark PB. et al, (2023), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 38, 2444 - 2455

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.

Journal article

Marx N. et al, (2023), Eur Heart J, 44, 4043 - 4140

Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.

Journal article

Writing Group for the CKD Prognosis Consortium None. et al, (2023), JAMA, 330, 1266 - 1277

SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe.

Journal article

SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration None., (2023), Eur Heart J, 44, 2544 - 2556

The authors reply.

Journal article

Chapman D. et al, (2023), Kidney Int, 104, 201 - 202

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.

Journal article

Inker LA. et al, (2023), Nat Med

Empagliflozin in Patients with Chronic Kidney Disease. Reply.

Journal article

Herrington WG. et al, (2023), N Engl J Med, 388, 2301 - 2302

Load More